SG11201806596TA - Pyridine derivative inhibiting raf kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof - Google Patents
Pyridine derivative inhibiting raf kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereofInfo
- Publication number
- SG11201806596TA SG11201806596TA SG11201806596TA SG11201806596TA SG11201806596TA SG 11201806596T A SG11201806596T A SG 11201806596TA SG 11201806596T A SG11201806596T A SG 11201806596TA SG 11201806596T A SG11201806596T A SG 11201806596TA SG 11201806596T A SG11201806596T A SG 11201806596TA
- Authority
- SG
- Singapore
- Prior art keywords
- same
- pyridine derivative
- cancer
- pharmaceutical composition
- growth factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160013643 | 2016-02-03 | ||
| PCT/KR2017/000387 WO2017135589A1 (ko) | 2016-02-03 | 2017-01-11 | 라프 키나제 및 혈관내피성장인자 수용체를 저해하는 피리딘 유도체, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806596TA true SG11201806596TA (en) | 2018-09-27 |
Family
ID=59499973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806596TA SG11201806596TA (en) | 2016-02-03 | 2017-01-11 | Pyridine derivative inhibiting raf kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10844062B2 (ko) |
| EP (1) | EP3412670B1 (ko) |
| JP (1) | JP6768838B2 (ko) |
| KR (1) | KR102031033B1 (ko) |
| CN (1) | CN109071543B (ko) |
| AU (1) | AU2017215928A1 (ko) |
| BR (1) | BR112018015980A2 (ko) |
| CA (1) | CA3013569A1 (ko) |
| CL (1) | CL2018002095A1 (ko) |
| PH (1) | PH12018501645A1 (ko) |
| RU (1) | RU2018131437A (ko) |
| SG (1) | SG11201806596TA (ko) |
| WO (1) | WO2017135589A1 (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102337870B1 (ko) * | 2020-02-03 | 2021-12-10 | 순천대학교 산학협력단 | 세포자멸사를 유도하는 치환된 다이아릴우레아 화합물 및 이를 포함하는 항암용 조성물 |
| US20240317752A1 (en) * | 2021-02-18 | 2024-09-26 | Black Diamond Therapeutics, Inc. | 6-substituted-9h-purine derivatives and related uses |
| WO2023183444A1 (en) * | 2022-03-24 | 2023-09-28 | Vibliome Therapeutics, Llc | Modulators of protein kinases |
| WO2023218245A1 (en) * | 2022-05-13 | 2023-11-16 | Voronoi Inc. | Heteroaryl derivative compounds, and pharmaceutical composition comprising thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2170887A2 (en) | 2007-06-07 | 2010-04-07 | Amgen Inc. | Heterocyclic compounds as raf kinase modulators |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| RU2550038C2 (ru) | 2010-12-02 | 2015-05-10 | Медпакто Инк. | Новое производное пуринилпиридиниламино-2,4-дифторфенилсульфонамида, его фармацевтически приемлемая соль, способ его получения и фармацевтическая композиция, обладающая ингибирующей активностью в отношении raf-киназы, содержащая данное соединение в качестве активного ингредиента |
| JP6031118B2 (ja) * | 2011-11-14 | 2016-11-24 | ケンタウルス バイオファーマ カンパニー リミテッド | キナーゼを調節する化合物、それらを含む組成物及びその用途 |
| CN103102349B (zh) | 2011-11-14 | 2017-03-15 | 北京赛林泰医药技术有限公司 | 蛋白激酶抑制剂及其组合物和用途 |
| CN103387576A (zh) | 2013-08-09 | 2013-11-13 | 中国药科大学 | 基于嘌呤结构的芳酰胺类Raf激酶抑制剂及其制备方法和用途 |
-
2017
- 2017-01-11 WO PCT/KR2017/000387 patent/WO2017135589A1/ko active Application Filing
- 2017-01-11 AU AU2017215928A patent/AU2017215928A1/en not_active Abandoned
- 2017-01-11 KR KR1020170004155A patent/KR102031033B1/ko active IP Right Grant
- 2017-01-11 CN CN201780021642.1A patent/CN109071543B/zh active Active
- 2017-01-11 EP EP17747634.8A patent/EP3412670B1/en active Active
- 2017-01-11 SG SG11201806596TA patent/SG11201806596TA/en unknown
- 2017-01-11 BR BR112018015980-8A patent/BR112018015980A2/ko not_active IP Right Cessation
- 2017-01-11 RU RU2018131437A patent/RU2018131437A/ru unknown
- 2017-01-11 CA CA3013569A patent/CA3013569A1/en active Pending
- 2017-01-11 JP JP2018560416A patent/JP6768838B2/ja not_active Expired - Fee Related
- 2017-01-11 US US16/074,950 patent/US10844062B2/en active Active
-
2018
- 2018-08-02 PH PH12018501645A patent/PH12018501645A1/en unknown
- 2018-08-03 CL CL2018002095A patent/CL2018002095A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017215928A1 (en) | 2018-08-23 |
| CN109071543A (zh) | 2018-12-21 |
| RU2018131437A3 (ko) | 2020-03-03 |
| WO2017135589A9 (ko) | 2017-10-19 |
| EP3412670B1 (en) | 2022-03-09 |
| US10844062B2 (en) | 2020-11-24 |
| CA3013569A1 (en) | 2017-08-10 |
| KR102031033B1 (ko) | 2019-11-18 |
| KR20170092453A (ko) | 2017-08-11 |
| CL2018002095A1 (es) | 2019-01-11 |
| JP6768838B2 (ja) | 2020-10-14 |
| EP3412670A4 (en) | 2019-07-17 |
| PH12018501645A1 (en) | 2019-05-27 |
| RU2018131437A (ru) | 2020-03-03 |
| BR112018015980A2 (ko) | 2018-12-18 |
| JP2019509334A (ja) | 2019-04-04 |
| CN109071543B (zh) | 2021-07-16 |
| US20190300531A1 (en) | 2019-10-03 |
| EP3412670A1 (en) | 2018-12-12 |
| WO2017135589A1 (ko) | 2017-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501645A1 (en) | Pyridine derivative inhibiting raf kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | |
| ZA201807256B (en) | Inhibitors of activin receptor-like kinase | |
| SA520411982B1 (ar) | Kirsten 2 مثبطات نظير الجين الورمي الفيروسي لساركوما جرذ (KRas) واستخدامها لعلاج السرطان | |
| PH12019502258A1 (en) | Isoquinolines as inhibitors of hpk1 | |
| MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| MY201925A (en) | Macrocyclic compounds and uses thereof | |
| SA519401954B1 (ar) | تركيبة صيدلانية للوقاية من أو معالجة سرطان تشتمل على صورة متعددة الشكل البلوري من تترا أرسينيك هيكسوكسويد | |
| PH12017500802B1 (en) | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof | |
| PH12019501220A1 (en) | Pharmaceutical composition for preventing or treating liver cancer, comprising tetraarsenic hexoxide crystalline polymorph | |
| MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| MX2019005526A (es) | Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa. | |
| ZA202000148B (en) | Heterocyclic inhibitors of atr kinase | |
| MX369159B (es) | Derivados de 3-(2-aminopiridin-4-il)-5-(3-hidroxipropinil)-1h-pirr olo[2,3-c]piridina como inhibidores de la nik para el tratamiento del cancer. | |
| MX2015013419A (es) | Cianoetilpirazolo piridonas aciclicas como inhibidores de janus quinasa. | |
| MX2016009581A (es) | Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso. | |
| MX2020003126A (es) | Derivados de iminopirimidina ciclicos como inhibidores de cinasa. | |
| PH12019501873A1 (en) | Pharmaceutical composition | |
| PH12019501252A1 (en) | Compositions and methods related to pyridinoylpiperidine 5-htif agonists | |
| MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
| MX369473B (es) | Derivado de indolona sustituido por pirrol, método de preparación del mismo, composición que comprende el mismo y uso del mismo. | |
| PH12017502081A1 (en) | Composition, containing quisqualis indica extract, for preventing or treating prostatic hyperplasia | |
| MX365315B (es) | Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa. | |
| NZ738247A (en) | 4-(3-pyrazolylamino)-benzimidazole compounds and their use as jak1 inhibitors | |
| PH12017500323A1 (en) | P38 map kinase inhibiting indanyl urea compounds | |
| MX2015015290A (es) | Compuestos furanona como inhibidores de quinasa. |